{"id":4424,"date":"2019-03-26T06:39:54","date_gmt":"2019-03-26T06:39:54","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4424"},"modified":"2019-03-26T06:39:54","modified_gmt":"2019-03-26T06:39:54","slug":"long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/he\/study_trials\/long-term-outcome-after-vemurafenib-braf-inhibitors-interruption-in-erdheim-chester-disease-love\/","title":{"rendered":"Long-term Outcome After Vemurafenib \/ BRAF Inhibitors Interruption in Erdheim-chester Disease (LOVE)"},"content":{"rendered":"<p><strong>\u05de\u05d8\u05e8\u05ea \u05d4\u05de\u05d7\u05e7\u05e8:<\/strong> ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been proposed for treating BRAF mutated histiocytoses.&nbsp; Other BRAF inhibitor interruption treatment should also be prospectively evaluated.<\/p>\n<p><strong>\u05d7\u05d5\u05e7\u05e8 \u05e8\u05d0\u05e9\u05d9:<\/strong> Julien Haroche, M.D., Ph.D., H\u00f4pitalPiti\u00e9-Salp\u00eatri\u00e8re, Paris FRANCE<\/p>\n<p><strong>\u05e4\u05e8\u05d8\u05d9 \u05d9\u05e6\u05d9\u05e8\u05ea \u05e7\u05e9\u05e8:<\/strong> Phone: +33 1 42 17 80 37 e-mail: julien.haroche@psl.aphp.fr<\/p>\n<p><strong>\u05de\u05e2\u05d5\u05e8\u05d1\u05d5\u05ea \u05d4\u05de\u05d8\u05d5\u05e4\u05dc \u05d4\u05e0\u05d3\u05e8\u05e9\u05ea:<\/strong> Patients and treating doctors are encouraged to contact Prof. Julien Haroche for more information.<\/p>\n<p><strong>\u05de\u05d6\u05d4\u05d4 \u05d1\u05d0\u05ea\u05e8 ClinicalTrials.gov:<\/strong> NCT02089724<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective: ECD patients with vemurafenib treatment seem to have a stable disease.&nbsp; This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[33],"class_list":["post-4424","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-observational"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials\/4424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/media?parent=4424"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/he\/wp-json\/wp\/v2\/study_trials_cat?post=4424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}